Tafenoquine/Chloroquine DDI Study

Summary

Tafenoquine/Chloroquine DDI Study is a clinical trial^[1].

Key Facts

• Tafenoquine/Chloroquine DDI Study is in the country of United States^[2].
• Tafenoquine/Chloroquine DDI Study's instance of is recorded as clinical trial^[3].
• Tafenoquine/Chloroquine DDI Study's start time is recorded as +2009-03-24T00:00:00Z^[4].
• Tafenoquine/Chloroquine DDI Study's end time is recorded as +2009-08-26T00:00:00Z^[5].
• Tafenoquine/Chloroquine DDI Study's sponsor is recorded as GSK^[6].
• Tafenoquine/Chloroquine DDI Study's number of participants is recorded as {'unit': '1', 'amount': '+68'}^[7].
• Tafenoquine/Chloroquine DDI Study's title is recorded as Safety, Tolerability, and Pharmacokinetic Study of Concomitant Chloroquine and Tafenoquine in Healthy Volunteers^[8].
• Tafenoquine/Chloroquine DDI Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[9].
• Tafenoquine/Chloroquine DDI Study's ClinicalTrials.gov ID is recorded as NCT00871156^[10].
• Tafenoquine/Chloroquine DDI Study's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+55'}^[11].
• Tafenoquine/Chloroquine DDI Study's research intervention is recorded as chloroquine^[12].
• Tafenoquine/Chloroquine DDI Study's research intervention is recorded as Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites^[13].
• Tafenoquine/Chloroquine DDI Study's research intervention is recorded as tafenoquine^[14].
• Tafenoquine/Chloroquine DDI Study's clinical trial phase is recorded as phase I clinical trial^[15].
• Tafenoquine/Chloroquine DDI Study's research site is recorded as GSK^[16].
• Tafenoquine/Chloroquine DDI Study's research subject recruitment status is recorded as completed^[17].
• Tafenoquine/Chloroquine DDI Study's study type is recorded as interventional study^[18].